What is it about?
The addition of SGLT2i as an add-on therapy for diabetes was associated with an increased risk of amputations, stent placement, or revascularization surgeries compared to DPP4i.
Featured Image
Read the Original
This page is a summary of: Use of SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes, Diabetes Care, December 2024, American Diabetes Association,
DOI: 10.2337/dc24-1546.
You can read the full text:
Contributors
The following have contributed to this page
